Although it may be associated with the differential epigenetic regulation of gene promoter activity of SYNGR3 [26], our results indicate that NURR1 transactivators may be helpful to maintain dopaminergic synaptic function via SYNGR3, thus presenting a potential therapeutic target to preserve neuronal function in PD (Figure 8). Here, NR4A2 is linked to Parkinson disease.